Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 260-375-3 | CAS number: 56773-42-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.01 mg/m³
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.08 mg/m³
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.01 mg/m³
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.08 mg/m³
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.003 mg/kg bw/day
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.003 mg/kg bw/day
DNEL related information
Workers - Hazard for the eyes
Additional information - workers
Tetraethylammonium perfluorooctanesulfonate (CAS 56773-42-3)
(PFOS)
DNELs
Repeated dose toxicity
A subchronic oral capsule study in monkeys and a dietary chronic toxicity and carcinogenicity study in rats was evaluated for the derivation of DNELs of PFOS
Basis for delineation of the DNEL:
Study (monkey study)
Repeated dose study
monkey, male, female,
subchronic oral capsule study for 182 days
monkey: 0 (control), 0.03, 0.15 or 0.75 mg/kg bw/d – male, female
via capsule
NOAEL, Effects
NOAEL = 0.15 mg/kg bw/d (male and female monkeys)
Effects:
Significant effects occurred only in the 0.75 mg/kg/day dose group and included compound related mortality in 2 of 6 male monkeys, decreased body weights, increased liver weights, lowered serum total cholesterol, lowered triiodothyronine concentrations (without evidence of hypothyroidism), and lowered estradiol levels. Hepatocellular hypertrophy and lipid vacuolation were present at term in the 0.75 mg/kg/day dose group.
Reference:
Seacat AM, Thomford PJ, Hansen KJ, Olsen GW, Case MT, Butenhoff JL (2002)
Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys
Toxicological Sciences 68, 249-264 (2002)
Reference
Study (rat study)
Repeated dose study
104-Week Dietary Chronic Toxicity and Carcinogenicity Study
rat, male, female,
chronic oral diet study for 104 weeks
rat: 0 (control), 0.5, 2, 5 or 20 ppm
– ca. 0, 0.025, 0.1, 0.25 or 1 mg/kg bw/d
male, female
via diet
Effects, NOAEL
NOAEL = ca. 0.025 mg/kg bw/d (male rats)
NOAEL = ca. 0.1 mg/kg bw/d (female rats)
Effects:
Based on the pathological findings in the liver, (centrilobular hypertrophy, centrilobular eosinophilic hepatocytic granules, centrilobular hepatocytic pigment, or centrilobular hepatocytic vacuolation ) the no-observed-adverse-effect level (NOAEL) for PFOS is considered to be 0.5 ppm in male rats and 2 ppm in female rats; the low observed-adverse-effect level (LOAEL) is 2 ppm in male rats and 5 ppm in female rats.
Reference:
3M Company (2002)
104-Week Dietary Chronic Toxicity and Carcinogenicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS) in Rats
1.) Long-term tocixity – systemic effects (workers) from the monkey study
Long-term oral or dermal route-systemic effects (worker) using default extrapolation factors:
NOAEL(monkey) from a subchronic toxicity study: 0.15 mg/kg bw/day
Penetration oral compared to dermal (both assumed 100%) 1
For interspecies differences monkey vs. human: 2
For remaining interspecies differences: 2.5
For intraspecies differences in workers: 5
For extrapolation of exposure duration subchronic to chronic: 2
For reliability of dose-response: 1
For quality of whole database: 1
Overall factor: 50
Worker DNEL long-term for oral or dermal route-systemic: 0.0030 mg/kg bw/day
1.) Long-term toxicity – systemic effects (workers) from the rat study
Long-term oral or dermal route-systemic effects (worker) using default extrapolation factors:
NOAEL(rat) from a chronic toxicity study: 0.025 mg/kg bw/day
Penetration oral compared to dermal (both assumed 100%) 1
For interspecies differences rat vs. human: 4
For remaining interspecies differences: 2.5
For intraspecies differences in workers: 5
For extrapolation of exposure duration: 1
For reliability of dose-response: 1
For quality of whole database: 1
Overall factor: 50
Worker DNEL long-term for oral or dermal route-systemic: 0.0005 mg/kg bw/day
Long-term inhalation route-systemic effects (worker) from the monkey study:
NOAEL(monkey) from a subchronic toxicity study: 0.15 mg/kg bw/day
Correction of the starting point according TGD Figure R.8-3:
Corrected inhalatory NAEC = Oral NOAELhuman : 2 (Allometric scaling factor for different species as compared to humans) = NAEL human x 70 kg bw : 10 m³ person
=> NAEC worker = 0.525 mg/m³
For interspecies differences monkey vs. human: 1 (according TGD Table
R.8-4. already covered by correction of starting point)
For remaining interspecies differences: 2.5
For intraspecies differences in workers: 5
For extrapolation of exposure duration subchronic to chronic: 2
For reliability of dose-response: 1
For quality of whole database: 1
Overall factor: 25
Worker DNEL long-term for inhalation exposure: 0.021 mg/m³
Long-term inhalation route-systemic effects (worker):
NOAEL(rat) from a subchronic toxicity study: 0.025 mg/kg bw/day
Correction of the starting point according TGD Figure R.8-3:
Corrected inhalatory NOAEC = Oral NOAEL (0.025 mg/kg) x 1/0.38 m³/kg x 6.7 m³/10m³ x 0.5
=> NOAEC worker = 0.022 mg/m³
For interspecies differences rat vs. human: 1 (according TGD Table
R.8-4. already covered by correction of starting point)
For remaining interspecies differences: 2.5
For intraspecies differences in workers: 5
For extrapolation of exposure: 1
For reliability of dose-response: 1
For quality of whole database: 1
Overall factor: 12.5
Worker DNEL long-term for inhalation exposure: 0.00176 mg/m³
The differences in the DNELs derived from the monkey and the rat study are caused by the different no-observed adverse effect levels (NOEALs ) of PFOS found in monkeys and rats. In both species effects on the liver (hypertrophy) as the most susceptible organ was found. However, rats accumulate PFOS in the target organ, whereas in monkeys an accumulation of PFOS in the liver was not substantiated. Thus the concentrations of PFOS in the liver are essential which may be different from serum levels in various species.
From limited human data it can be concluded, the ratio of the concentrations of PFOS in liver and serum in humans and monkeys is similar.
Therefore the data of the monkey study are more reliable.
The German MAK Commission defined in 2010 a workplace limit value of 0.01 mg/m³ ((DFG 2010). This value is lower, but overall in line with the values derived with the above mentioned calculations. Taking into consideration the uncertainties regarding species extrapolation this value of 0.01 mg/m³ will be used as long-term DNEL for workers for inhalation exposure.
2.) Short-term toxicity – systemic effects (workers)
Concerning the systemic effects an exceeding factor of 8 for inhalation toxicity based on the DNEL for long term exposure seems justified. For oral and dermal toxicity no exceeding factor is recommend.
Worker DNELshort-term for oral or dermal route-systemic: 0.003 mg/kg bw/day
Worker DNEL short-term for inhalation exposure: 0.08 mg/m³
Conclusion (systemic effects):
Worker DNEL long-term for oral or dermal route-systemic: 0.003 mg/kg bw/day
Worker DNEL long-term for inhalation exposure: 0.01 mg/m³
Worker DNELshort-term for oral or dermal route-systemic: 0.003 mg/kg bw/day
Worker DNEL short-term for inhalation exposure: 0.08 mg/m³
3.) Reproductive Toxicity – systemic effects (workers)
In a 2 generation study on rats a NOAEL of 0.4 mg/kg bw/ d for developmental toxicity was found.
For the developmental toxicity/teratogenicity a NOAEL of 0.3 mg/kg bw/d for pre- and postnatal toxicity was determined. In a prenatal immunotoxicty study in mice the NOAEL was 0.1 mg/kg bw/d.
Therefore the derivation of a separate DNEL for reproductive toxicity is not necessary, because the DNEL for repeated dose toxicty (0.025 mg/kg bw/d in rats) covers both endpoints.
4. Long-term and short-term dermal or inhalation route - local effects (worker)
In rabbits, PFOS was not irritating to the skin (OECD TG 404), and not irritating to the eyes (OECD TG 405).
A LLNA in mice (OECD 429 and 406) was negative up to and including a 50% concentration.
Therefore the DNELs for systemic effects also applies to local effects:
Conclusion (local effects):
Worker DNEL long-term for oral or dermal route: 0.003 mg/kg bw/day
Worker DNEL long-term for inhalation exposure: 0.01 mg/m³
Worker DNELshort-term for oral or dermal route: 0.003 mg/kg bw/day
Worker DNEL short-term for inhalation exposure: 0.08 mg/m³
References:
• Seacat AM, Thomford PJ, Hansen KJ, Olsen GW, Case MT, Butenhoff JL –Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys, Toxicol Sci 68, 249-264 (2002)
• Mihail F, Tetraaethylammoniumperfluoroctansulfonat - Untersuchungen auf Reizwirkung an der Haut und am Auge von Kaninchen, Bayer - Institut fuer Toxikologie Wuppertal-Elberfeld, 1975
• Luebker DJ, Case MT, York RG, Moore JA, Hansen KJ, Butenhoff JL (2005), Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats, Toxicology 215, 126-148
• Butenhoff JL, , Ehresman DJ, Chang SC, Parker FA,, Stump DG (2009), Gestational and lactational exposure to potassium perfluorooctanesulfonate (K+PFOS) in rats: developmental neurotoxicity. Reprod Toxicol 27, 319-330
• Keil DE, Mehlmann T, Butterwoth L, Peden-Adams MM (2008), Gestational exposure to perfluorooctane sulfonate suppresses immune function in B6C3F1 mice, Toxicol Sci 103, 77-85
• ECHA – Guidance on information requirements and chemical safety assessment, Chapter R. 8, Characterisation of dose [concentration]-response for human health, page 64
General Population - Hazard via inhalation route
Systemic effects
Acute/short term exposure
DNEL related information
Local effects
Acute/short term exposure
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Acute/short term exposure
DNEL related information
General Population - Hazard via oral route
Systemic effects
Acute/short term exposure
DNEL related information
General Population - Hazard for the eyes
Additional information - General Population
tetraethylammonium heptadecafluorooctanesulfonate is only used in idustrial processes (e.g. metal (chromium) plating) and the general population is not exposed to the compound. Therefore the derivation of a DNEL for the general population is not necessary.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)